share_log

Altamira Therapeutics | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Thomas Meyer(1.2%)

SEC announcement ·  Mar 13 11:08
Summary by Moomoo AI
Thomas Meyer, an investor in Altamira Therapeutics, has filed an amendment to his Schedule 13D with the U.S. Securities and Exchange Commission, disclosing recent purchases of the company's common stock. The amendment, dated March 13, 2024, reports that Meyer now beneficially owns 22,297 common shares of Altamira Therapeutics, which represents 1.2% of the company. This stake includes 20,000 common shares and the right to acquire an additional 2,297 shares through options and warrants exercisable within 60 days. The filing details two separate transactions: the purchase of 51 common shares on December 29, 2023, at $3.24 per share, and 17,350 common shares on March 11, 2024, at $1.864 per share, both funded with personal funds. Meyer holds sole voting and dispositive power over these shares. The amendment to Schedule 13D does not alter any previously reported information except as explicitly stated.
Thomas Meyer, an investor in Altamira Therapeutics, has filed an amendment to his Schedule 13D with the U.S. Securities and Exchange Commission, disclosing recent purchases of the company's common stock. The amendment, dated March 13, 2024, reports that Meyer now beneficially owns 22,297 common shares of Altamira Therapeutics, which represents 1.2% of the company. This stake includes 20,000 common shares and the right to acquire an additional 2,297 shares through options and warrants exercisable within 60 days. The filing details two separate transactions: the purchase of 51 common shares on December 29, 2023, at $3.24 per share, and 17,350 common shares on March 11, 2024, at $1.864 per share, both funded with personal funds. Meyer holds sole voting and dispositive power over these shares. The amendment to Schedule 13D does not alter any previously reported information except as explicitly stated.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more